What Is a Bivalent Vaccine and How Does It Work?

A bivalent vaccine is a vaccine designed to protect against two distinct strains or types of a pathogen in a single dose. The word “bivalent” simply means “two-valued,” and it distinguishes these vaccines from monovalent ones (which target a single strain) and from broader multivalent vaccines like the quadrivalent or nonavalent HPV shots. The concept has been in use for decades across diseases ranging from polio to meningitis to human papillomavirus, but it became a household term during the COVID-19 pandemic when updated mRNA boosters combined the original SARS-CoV-2 spike protein with a newer Omicron variant spike. How these vaccines actually train the immune system, and what complicates that training, turns out to be more interesting than the straightforward label suggests.

How a Bivalent Vaccine Trains the Immune System

Every vaccine works by showing the immune system a harmless preview of a pathogen so the body can build defenses before a real infection arrives. A bivalent vaccine does this with two previews instead of one, each representing a different version of the pathogen. In the case of COVID-19 mRNA bivalent boosters, those two previews were two different spike protein sequences encoded in separate mRNA strands, packaged together in the same lipid nanoparticle injection. For oral polio vaccine, the two previews are live-attenuated versions of poliovirus types 1 and 3. The delivery system varies, but the core logic is the same: expose your immune cells to two targets, and they learn to recognize both.

When a bivalent vaccine enters your body, immune cells called antigen-presenting cells pick up the two different protein targets and display fragments of them to T cells and B cells. This kicks off two parallel tracks of immune learning. B cells that recognize either target begin producing antibodies specific to each strain. T cells, meanwhile, learn to identify and kill cells already infected by either version of the pathogen. Research on bivalent fusion proteins has shown that a well-designed bivalent approach can stimulate both arms of immunity at once, with one study in an animal model of bacterial infection finding that bivalent immunization triggered both antibody production and strong T cell responses, resulting in complete survival after a lethal bacterial challenge 120 days later, while animals given single-antigen vaccines fared far worse.¹

The reason bivalent vaccines exist rather than just updating to the newest strain is strategic. By including two strain components, vaccine designers can try to cover a wider stretch of the pathogen’s evolutionary landscape. If the pathogen is drifting genetically, a vaccine containing both an older and a newer variant may help the immune system recognize not just those two targets but also intermediate variants that share features with both. Whether that cross-coverage materializes in practice depends heavily on how different the two strains are and on what your immune system has encountered before.

Bivalent Vaccines That Existed Long Before COVID

The COVID-era boosters put the word “bivalent” into everyday conversation, but the concept has a long track record in public health. Two of the most widespread examples are the bivalent oral polio vaccine (bOPV) and the bivalent HPV vaccine (Cervarix).

Bivalent oral polio vaccine contains weakened forms of poliovirus types 1 and 3, the two types still considered a threat in global eradication efforts after type 2 was declared eradicated in the wild. Clinical trials of bOPV have consistently shown strong immune responses, with more than 96% of infants achieving seroconversion and seroprotection against both poliovirus types.² One practical wrinkle with bOPV, relevant in lower-income settings where it is most heavily used, is that diarrheal illness at the time of vaccination can blunt immune responses. A study of infants in Nepal found that those with diarrhea had a meaningfully reduced immune response, particularly against type 3 poliovirus, where infants with more than five loose stools per day had roughly a third of the odds of responding well compared to healthy infants.³

The bivalent HPV vaccine, marketed as Cervarix, targets HPV types 16 and 18, which together cause the majority of cervical cancers. It sits alongside the quadrivalent and nonavalent HPV vaccines that cover more types. Despite targeting fewer strains, the bivalent HPV vaccine performs comparably to its broader siblings against HPV 16/18 specifically, and has also shown some degree of cross-protection against related HPV types not explicitly included in the formulation.⁴ That cross-protection effect illustrates one of the genuine advantages of a well-designed bivalent vaccine: by targeting the right two strains, you can sometimes get bonus coverage against their close relatives for free.

The COVID-19 Bivalent Boosters

In late 2022, updated COVID-19 mRNA boosters from both Pfizer-BioNTech and Moderna were authorized as bivalent formulations. Each contained mRNA encoding two spike proteins: one matching the original (ancestral) SARS-CoV-2 strain and one matching Omicron subvariants (BA.1 for the first wave of approvals, then BA.4/5). The rationale was straightforward: the original monovalent vaccines had been losing ground against Omicron sublineages, and adding an Omicron component might restore some of that lost protection while maintaining coverage against the ancestral strain.

The real-world effectiveness data were encouraging in the places where it matters most. A large US study of the Moderna bivalent booster found that vaccine effectiveness against COVID-19 hospitalization was roughly 83%, and effectiveness against death from COVID-19 in hospitalized patients was about 90%.⁵ Against milder, medically attended infections, the picture was more modest, as expected given the difficulty any vaccine faces in blocking upper respiratory tract infection entirely. The bivalent booster also broadened the range of antibody responses, increasing antibodies against the spike protein in both the bloodstream and nasal passages, though these waned over six months.⁶

Protein-based bivalent COVID vaccines also entered the picture. An Argentine-developed protein subunit vaccine (ARVAC) was tested as a bivalent booster and showed seroconversion rates above 90% against multiple SARS-CoV-2 variants, including the ancestral strain, Gamma, Omicron, XBB, and JN.1, as well as cross-neutralization against the related SARS-CoV-1 virus.⁷ This mattered because it demonstrated the bivalent concept was not locked to the mRNA platform alone.

Immune Imprinting and Why Bivalent Does Not Always Mean Better

One of the most scientifically interesting findings to come out of the bivalent COVID booster era was the phenomenon of immune imprinting, sometimes called “original antigenic sin.” The idea is that your immune system, once trained on a particular version of a pathogen, tends to reach back into its memory of that first encounter when it sees something new that looks even a little similar. Instead of building entirely fresh antibodies against the new component, it may boost the old response instead.

For the COVID bivalent boosters, this was a real constraint. Research showed that the ancestral spike component in the bivalent vaccine effectively dominated the immune response. People who had received multiple doses of the original monovalent vaccine did not generate notably better antibodies against the Omicron BA.5 spike after receiving the bivalent booster, compared to what they would have produced from the ancestral component alone. By contrast, people who were exposed to the BA.5 spike through actual infection, without prior ancestral vaccination, did produce strong BA.5-specific antibodies.⁸ In other words, the immune system’s memory of the original spike overshadowed the newer variant component. Imprinting from three doses of monovalent vaccine could be partially overcome by a breakthrough Omicron infection, but not by the bivalent booster alone.⁹

This helps explain a puzzling observation: the BA.5 bivalent booster produced high neutralizing antibody levels against BA.4/5 when measured shortly after vaccination, but it did not generate strong neutralization against subsequent Omicron subvariants like BA.2.75.2, BQ.1.1, or XBB.1, which had drifted further from the vaccine targets.¹⁰ The bivalent formulation was better than the original monovalent vaccine, but the advantage was smaller than many had hoped, partly because immune imprinting kept pulling the response back toward ancestral-like antibodies.

Imprinting is not unique to COVID vaccines. It has been observed with influenza for decades, which is one reason flu vaccines are updated annually to try to stay ahead of drift. But the speed of SARS-CoV-2 evolution made it an especially visible problem in the bivalent vaccine context, and it became a major factor in the decision to eventually move away from bivalent formulations and toward monovalent updated boosters targeting only the newest circulating variant.

How Long Does Bivalent Protection Last

Like most vaccine-induced immunity, the antibody levels generated by bivalent COVID boosters declined over time. A study measuring neutralizing antibody titers about five and a half months after a bivalent booster found that levels had dropped compared to the early post-vaccination peak. The decline was steeper in people who had not been previously infected and more pronounced for newer Omicron variants that the vaccine was less precisely matched against.¹¹ This is consistent with the broader pattern seen across COVID vaccines: circulating antibodies wane over months, though memory B cells and T cells often persist longer and can mount a rapid response upon re-exposure.

People with hybrid immunity, meaning they had been both vaccinated and previously infected, fared better. A Japanese study found that bivalent vaccination combined with prior infection enhanced both antibody responses and innate immune protection against later-emerging Omicron subvariants like XBB.1.16 and EG.5.1.1.¹² This synergy between natural infection and vaccination produced broader and more durable immunity than either alone, which partly offset the waning issue.

Safety Profile Compared to Monovalent Vaccines

The safety data on bivalent COVID vaccines presented a mixed picture depending on who was studied and how side effects were measured. A European study of adults comparing bivalent and monovalent second booster doses found that the bivalent group reported significantly more side effects overall, with about 88% of bivalent recipients reporting at least one adverse reaction compared to roughly 53% in the monovalent group. Bivalent recipients also had slightly longer periods of inability to work.¹³ These were the familiar vaccine side effects like sore arms, fatigue, and headache rather than serious complications, but the frequency was higher.

Interestingly, the pattern was different in adolescents. A Korean surveillance study of 12- to 17-year-olds found lower rates of reported adverse events after bivalent boosters than after monovalent boosters, with both local and systemic reactions less common in the bivalent group. The rate of myocarditis and pericarditis, a rare side effect of particular concern in young males, was not significantly different between the two vaccine types.¹⁴ The discrepancy likely reflects differences in dose number (adolescents were earlier in their vaccination sequence), reporting methodology, and age-related immune reactivity. The overall takeaway across populations was that bivalent boosters had a side-effect profile broadly comparable to what people had come to expect from COVID mRNA vaccines, with no new safety signals of concern.

Bivalent Vaccines in Immunocompromised People

People with weakened immune systems, whether from organ transplants, HIV, autoimmune conditions requiring immunosuppressive drugs, or other causes, have consistently responded less robustly to COVID vaccines. Bivalent boosters improved matters but did not close the gap entirely. A Swiss study of people living with HIV and solid organ transplant recipients found that bivalent boosters produced a roughly five-fold increase in antibody concentrations four weeks after vaccination in most subgroups. However, lung transplant recipients were a notable exception and did not achieve this boost. By six months, antibody levels had fallen by about half across the board.¹⁵

A separate longitudinal study tracking people with various immunocompromising conditions found that Omicron-adapted booster doses (including bivalent formulations) were especially valuable for this group because they triggered new B cell responses specific to the Omicron variant, something the original vaccines had struggled to achieve in immunocompromised individuals. Still, a subset of low-responders persisted even after multiple vaccine doses.¹⁶ These findings have practical implications for scheduling: people with compromised immune systems often benefit from additional doses and closer monitoring of their antibody levels, and the specific type of immunocompromising condition matters in predicting who will respond well.

Bivalent Vaccines in Veterinary Medicine

The bivalent concept is not limited to human medicine. Livestock producers routinely use combination vaccines, and the bivalent approach is common in poultry and swine farming. One animal health example involves a bivalent vaccine combining porcine circovirus type 2 (PCV2) with Mycoplasma hyopneumoniae, two pathogens that cause respiratory and wasting diseases in pigs. Field trials comparing this bivalent vaccine to a trivalent version (which added a second PCV2 subtype) found that the trivalent vaccine produced better growth performance and lower pathogen loads, suggesting that for pig diseases where multiple subtypes circulate, even the bivalent approach may leave gaps.¹⁷

In poultry, researchers have explored using live attenuated bacteria as carriers for bivalent vaccine delivery. One approach used an attenuated Salmonella strain engineered to express influenza virus antigens, creating a single oral vaccine that protected chickens against both avian influenza and fowl typhoid simultaneously. The system worked by exploiting two different gene promoters to drive antigen production in both bacterial and animal cells, stimulating a broad immune response across multiple pathways.¹⁸ These agricultural applications highlight how the bivalent principle scales across species and delivery platforms.

Manufacturing a Two-in-One Vaccine

Combining two antigens in a single vial introduces engineering challenges that a monovalent product does not face. The two components must remain stable together, at the same temperature, for the same shelf life, without interfering with each other. For mRNA-based bivalent vaccines, this means packaging two different mRNA sequences in lipid nanoparticles of consistent size and ensuring neither degrades faster than the other. Testing of one bivalent mRNA COVID vaccine showed that the finished product had an average particle size of about 72 nanometers with very uniform distribution, and that it maintained stable physical and chemical characteristics under storage at various temperatures for about a month, comparable to its monovalent counterparts.¹⁹

For protein-based and bacterial vaccines, formulation challenges are different but no less real. A study on a multivalent bacterial vaccine candidate demonstrated that the right combination of buffer, stabilizers, and surfactants could keep a complex multi-component product stable for three years at standard refrigerator temperatures.²⁰ This kind of long-term stability is critical for global distribution, especially in regions with unreliable cold chains. The manufacturing bar for a bivalent or multivalent vaccine is higher than for a monovalent one, but modern formulation science has become quite good at clearing it.

Where Bivalent Fits in the Larger Vaccine Landscape

The move from monovalent to bivalent COVID vaccines in 2022 was, in hindsight, a transitional step. By 2023 and into 2024, regulators shifted to monovalent updated boosters targeting only the most recent circulating variant, partly because of the imprinting problem and partly because the original strain component had become irrelevant as it no longer circulated. The lesson was not that the bivalent approach failed but that the specific pairing of ancestral-plus-Omicron had diminishing returns as the virus evolved further away from both components.

Looking ahead, some researchers are pushing past the bivalent model entirely, pursuing universal coronavirus vaccines that would target highly conserved regions of the spike protein, shared across many variants and even across different coronaviruses. Strategies under investigation include mosaic constructs that display spike fragments from many variants on a single nanoparticle, multi-epitope vaccines focused on the receptor-binding domain, and designs centered on the S2 subunit of the spike protein, which mutates less than the S1 region that current vaccines target.²¹ Whether any of these pans out remains to be seen, but they represent the logical next step beyond the bivalent concept: instead of covering two strains, cover all of them at once by targeting what they have in common.

For now, though, the bivalent approach remains a workhorse in global health. Bivalent oral polio vaccine continues to be administered to millions of children worldwide. Bivalent HPV vaccination programs run in dozens of countries. And the bivalent concept continues to inform new vaccine designs across infectious diseases. The term may have peaked in public awareness during the pandemic, but the underlying strategy of training the immune system against two targets at once is older, simpler, and more durable than any single product it has been attached to.